Surgery or observation after successful liver cancer treatment
Part of Cancer, Digestive system clinical trials.
This study compares surgery versus watch-and-wait for people whose liver cancer shrank significantly after treatment. It aims to find out if surgery is always needed or if watching closely is just as good.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a type of liver cancer that was first considered not removable by surgery, but after treatment, it shrank a lot.
- Your liver function is good enough (e.g., a Child-Pugh A score).
- You have no active other cancers, no serious bleeding, and no infections.
- If you have hepatitis B, you agree to take antiviral medication during the study.
- You are not pregnant or planning to become pregnant, and you agree to use birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can lower the chance of liver cancer coming back in people who have high-risk features. It may help patients with early-stage liver cancer that can be removed surgically.
This study tests whether giving a combination of two drugs—tislelizumab (an immunotherapy that helps your immune system fight cancer) and lenvatinib (a targeted therapy that blocks tumor growth)—before surgery can improve outcomes for people with early-stage liver cancer (a single tumor 2-5 cm) when the surgery is likely to have a narrow margin. You would receive the drugs for a few weeks before your scheduled surgery, and then have the surgery as planned. This approach may help reduce the chance of the cancer coming back.
This study tracks patients with liver cancer who have had surgery to see how often the cancer comes back. It may help doctors better understand and predict recurrence.
This trial looks at whether people with an initially untreatable liver cancer that has shrunk or disappeared after drug therapy should have surgery or just continue monitoring. It aims to see which approach helps people live longer.
This study compares two options for people whose liver cancer has completely disappeared after treatment: having surgery to remove the remaining affected area, or continuing to monitor closely without immediate surgery. It aims to find out which approach helps people live longer and live better.
This study tests a combination of treatments to shrink liver cancer that cannot be removed with surgery at first. The goal is to make the tumor small enough for surgery or to disappear completely, and then either have surgery or continue the treatment.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.